133 related articles for article (PubMed ID: 17828534)
1. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy.
Reske SN; Blumstein NM; Glatting G
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):9-17. PubMed ID: 17828534
[TBL] [Abstract][Full Text] [Related]
2. Extended nodal radiotherapy for prostate cancer relapse guided with [11C]-choline PET/CT: ten-year results in patients enrolled in a prospective trial.
Fodor A; Brombin C; Deantoni CL; Giannini L; Ferrario F; Villa SL; Mangili P; Rancoita PMV; Cozzarini C; Picchio M; Del Vecchio A; Fiorino C; Di Serio MCS; Chiti A; Di Muzio NG
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):590-603. PubMed ID: 37747578
[TBL] [Abstract][Full Text] [Related]
3. Assessing the effectiveness of MRI,
Virarkar MK; Gruschkus SK; Ravizzini GC; Vulasala SSR; Javadi S; Bhosale P
Pol J Radiol; 2024; 89():e196-e203. PubMed ID: 38783912
[TBL] [Abstract][Full Text] [Related]
4. Analysis of enhanced CT imaging signs and clinicopathological prognostic factors in hepatoid adenocarcinoma of stomach patients with radical surgery: a retrospective study.
Yan XY; Ju HY; Hou FJ; Li XT; Yang D; Tang L; Wang YK; Li ZW; Sun YS; Gao SY
BMC Med Imaging; 2023 Oct; 23(1):167. PubMed ID: 37884901
[TBL] [Abstract][Full Text] [Related]
5. Role of
Altini C; Asabella AN; Tramacere F; Sardaro A; Pisani AR; Castelluccia A; Rubini D; Ferrari C
Mol Imaging Radionucl Ther; 2024 Feb; 33(1):1-10. PubMed ID: 38390705
[TBL] [Abstract][Full Text] [Related]
6. A new concept for the production of
Wenz J; Arndt F; Samnick S
EJNMMI Radiopharm Chem; 2022 Mar; 7(1):6. PubMed ID: 35347490
[TBL] [Abstract][Full Text] [Related]
7. F-18 fluorocholine positron emission tomography- computed tomography in initial staging and recurrence evaluation of prostate carcinoma: A prospective comparative study with diffusion-weighted magnetic resonance imaging and whole-body skeletal scintigraphy.
Vatsa R; Kumar R; Shukla J; Rana N; Vadi SK; Lal A; Singh SK; Mittal BR
World J Nucl Med; 2021; 20(2):156-163. PubMed ID: 34321968
[TBL] [Abstract][Full Text] [Related]
8. Detection Rate of
Takesh M; Odat Allh K; Zechmann CM
Contrast Media Mol Imaging; 2020; 2020():4320178. PubMed ID: 32848525
[TBL] [Abstract][Full Text] [Related]
9. Imaging assessment of local recurrence of prostate cancer after radical prostatectomy.
Magnetta MJ; Casalino D; Heller MT
Abdom Radiol (NY); 2020 Dec; 45(12):4073-4083. PubMed ID: 32248258
[TBL] [Abstract][Full Text] [Related]
10. Magnetic Resonance-Guided Prostate Ablation.
Woodrum DA; Kawashima A; Gorny KR; Mynderse LA
Semin Intervent Radiol; 2019 Dec; 36(5):351-366. PubMed ID: 31798208
[TBL] [Abstract][Full Text] [Related]
11. Imaging for Target Delineation and Treatment Planning in Radiation Oncology: Current and Emerging Techniques.
Stieb S; McDonald B; Gronberg M; Engeseth GM; He R; Fuller CD
Hematol Oncol Clin North Am; 2019 Dec; 33(6):963-975. PubMed ID: 31668214
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of PET/CT in prostate cancer management.
Rayn KN; Elnabawi YA; Sheth N
Transl Androl Urol; 2018 Oct; 7(5):844-854. PubMed ID: 30456187
[TBL] [Abstract][Full Text] [Related]
13. Interpretation of 11C-choline PET/CT for the diagnosis of local relapse in radically treated prostate cancer.
Matti A; Lima GM; Zanoni L; Pultrone C; Schiavina R; Lodi F; Fanti S; Nanni C
Eur J Hybrid Imaging; 2017; 1(1):5. PubMed ID: 29782589
[TBL] [Abstract][Full Text] [Related]
14. Trigger pSA predicting recurrence from positive choline PET/CT with prostate cancer after initial treatment.
Wei J; Zhu H; Liao X
Oncotarget; 2018 Mar; 9(18):14630-14641. PubMed ID: 29581869
[TBL] [Abstract][Full Text] [Related]
15. The relationship between local recurrences and distant metastases in prostate cancer: can
Giovacchini G; Ciarmiello A; Giovannini E; Fodor A; Cozzarini C; Mapelli P; Incerti E; Di Muzio N; Gianolli L; Picchio M
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):962-969. PubMed ID: 29453702
[TBL] [Abstract][Full Text] [Related]
16. Anatomic and Molecular Imaging in Prostate Cancer.
Miller ET; Salmasi A; Reiter RE
Cold Spring Harb Perspect Med; 2018 Mar; 8(3):. PubMed ID: 28710256
[TBL] [Abstract][Full Text] [Related]
17. Delineation of the Prostate Bed: The "Invisible Target" Is Still an Issue?
Latorzeff I; Sargos P; Loos G; Supiot S; Guerif S; Carrie C
Front Oncol; 2017; 7():108. PubMed ID: 28620579
[TBL] [Abstract][Full Text] [Related]
18. PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.
Giovacchini G; Giovannini E; Leoncini R; Riondato M; Ciarmiello A
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1751-1776. PubMed ID: 28409220
[TBL] [Abstract][Full Text] [Related]
19. MRI-Guided Prostate Biopsy of Native and Recurrent Prostate Cancer.
Woodrum DA; Gorny KR; Greenwood B; Mynderse LA
Semin Intervent Radiol; 2016 Sep; 33(3):196-205. PubMed ID: 27582607
[TBL] [Abstract][Full Text] [Related]
20. Comparison of
Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
